MASLD is associated with altered levels of adipsin and plasminogen activator inhibitor-1 (PAI-1), whereas adipsin is markedly higher in obese MASLD patients than in normal-weight individuals (190, 191). This evidence concerns the gene CFD and metabolic dysfunction-associated steatotic liver disease.